Skip to content

Released Aug 16, 2021, during market hours

10-Q filed Aug 16, 2021, 47 days after period end · 0000950170-21-001486

Q2 2021 · 10-Q
Revenue—
Net Income-$55.80MN/M vs Q2 2020N/M vs Q1 2021
EPS Diluted-$1.07N/M vs Q2 2020N/M vs Q1 2021
Operating Income-$55,689,000N/M
Operating Cash Flowderived-$5,939,000N/M
Free Cash Flowderived-$6,235,000N/M

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ2 2021Q2 2020Q2 2019
Net Income-$55.80M-$5.56M-$8.81M
EPS Diluted-$1.07-$0.41-$1.33

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR